It has been demonstrated that treatments with 4’-(p-toluenesulfonylamido)-4-hydroxychalcone (TSAHC) or its derivatives could decrease pY577FAK and p27kip1 levels in HCC cells [113]. The gene discussed is CDKN1B; the disease is hepatocellular carcinoma.